Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2651 - 2675 of 3671 in total

GDC-0623

GDC-0623 has been used in trials studying the treatment of Solid Cancers.
Investigational

AZD-0328

AZD0328 has been used in trials studying the treatment and basic science of Schizophrenia and Alzheimer's Disease.
Investigational

GDC-0810

ARN-810 has been used in trials studying the basic science and treatment of Breast Cancer.
Investigational

GDC-0917

CUDC-427 has been used in trials studying the treatment of LYMPHOMA and Solid Cancers.
Investigational

GDC-0152

GDC-0152 has been used in trials studying the treatment of Solid Cancers.
Investigational

CYNK-001

CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Investigational

BSK02

BSK02 is a Sperm Protein-17 oral microparticle vaccine
Investigational

ETBX-011

ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Investigational

ETBX-021

Investigational

ETBX-061

Investigational

AVR-RD-01

AVR-RD-01 is an investigational ex vivo lentiviral gene therapy developed by AVROBIO Inc. It consists of autologous CD34+ cells that transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence. AVR-RD-01 is being investigated for Fabry Disease.[L45963, L45968]
Investigational

ABSK-012

Investigational

PLG-0206

PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational

BRG01

BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.
Investigational

LAVA-051

LAVA-051 is a humanized Vγ9Vδ2-T cell-engaging bispecific antibody.
Investigational

OSSM-007

OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells.
Investigational

AVR-RD-05

AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational

ANEB-001

ANEB-001 is under investigation in clinical trial NCT05282797 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test).
Investigational

Galinpepimut-S

Investigational

Parsaclisib

Parsaclisib is under investigation in clinical trial NCT03126019 (An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)).
Investigational

Zalsenertant tetraxetan lutetium Lu-177

Investigational

Rilotumumab

Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
Investigational

Acetylcysteine zidrimer

Investigational

Finotonlimab

Finotonlimab is under investigation in clinical trial NCT04560894 (SCT-I10A Plus SCT510 Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma).
Investigational

GPI-0100

GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy.
Investigational
Displaying drugs 2651 - 2675 of 3671 in total